TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

被引：0
|
作者：
Jolanta Kupryjanczyk
Ewa Kraszewska
Izabela Ziolkowska-Seta
Radoslaw Madry
Agnieszka Timorek
Janina Markowska
Jerzy Stelmachow
Mariusz Bidzinski
机构：
[1] the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,Department of Molecular Pathology
[2] Medical Center for Postgraduate Education,Department of Gastroenterology and Hepatology
[3] the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,Department of Gynecologic Oncology
[4] Warsaw Medical University and Brodnowski Hospital,Department of Pathology, IInd Faculty of Medicine
[5] Medical University,Chair of Gynecologic Oncology
[6] Warsaw Medical University and Brodnowski Hospital,Chair and Department of Obstetrics, Gynecology and Oncology, IInd Faculty of Medicine
来源：
BMC Cancer | / 8卷
关键词：
Ovarian Cancer Patient; Clear Cell Carcinoma; Poor Tumor Differentiation; TP53 Status; TP53 Protein;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Combination of a three-microRNA signature and TP53 genotype predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma
    Shiraishi, Kouya
    Saito, Motonobu
    Kohno, Takashi
    CANCER RESEARCH, 2015, 75 (22)
  • [22] Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with "platinum-resistant" ovarian cancer (PROC): Real-world recent cohort study
    Rumyantsev, A.
    Israelyan, E. R.
    Pokataev, I.
    Glazkova, E.
    Tsareva, A.
    Ablyametova, A.
    Letuchikh, A.
    Ignatova, E.
    Anokhin, A.
    Abramov, M.
    Shevchuk, A.
    Tyulyandina, A.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S586 - S586
  • [23] Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy
    Zavarykina, T. M.
    Tyulyandina, A. S.
    Khokhlova, S. V.
    Khabas, G. N.
    Asaturova, A. V.
    Nosova, Yu. A.
    Brenner, P. K.
    Kapralova, M. A.
    Atkarskaya, M. V.
    Khodyrev, D. S.
    Burdennyi, A. M.
    Loginov, V. I.
    Stenina, M. B.
    Sukhikh, G. T.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 169 (04) : 486 - 490
  • [24] Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy
    T. M. Zavarykina
    A. S. Tyulyandina
    S. V. Khokhlova
    G. N. Khabas
    A. V. Asaturova
    Yu. A. Nosova
    P. K. Brenner
    M. A. Kapralova
    M. V. Atkarskaya
    D. S. Khodyrev
    A. M. Burdennyi
    V. I. Loginov
    M. B. Stenina
    G. T. Sukhikh
    Bulletin of Experimental Biology and Medicine, 2020, 169 : 486 - 490
  • [25] The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy
    Li, Yueyi
    Wang, Hang
    Chen, Ming
    Ma, Xuelei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Randomized pharmacokinetic evaluation of subcutaneous versus intravenous palonosetron in cancer patients treated with platinum-based chemotherapy
    Del Barrio, A.
    Sadaba, B.
    Gurpide, A.
    Campanero, M. A.
    Zudaire, M.
    Lopez-Picazo, J. M.
    Azanza, J. R.
    Manubens, A.
    Gomez-Guiu, A.
    Perez-Garcia, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] RANDOMIZED PHARMACOKINETIC EVALUATION OF SUBCUTANEOUS VERSUS INTRAVENOUS PALONOSETRON IN CANCER PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Del Barrio, A.
    Sadaba, B.
    Gurpide, A.
    Campanero, M. A.
    Zudaire, M. E.
    Lopez Picazo, J. M.
    Azanza, J. R.
    Manubens, A.
    Gomez Guiu, A.
    Perez Gracia, J. L.
    ANNALS OF ONCOLOGY, 2010, 21 : 381 - 381
  • [28] Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Shintani, Yasushi
    Sekine, Ikuo
    Shukuya, Takehito
    Takayama, Koichi
    Inoue, Akira
    Okamoto, Isamu
    Kiura, Katsuyuki
    Takahashi, Kazuhisa
    Yamamoto, Nobuyuki
    Kawaguchi, Tomoya
    Miyaoka, Etsuo
    Yoshino, Ichiro
    Date, Hiroshi
    BMC CANCER, 2022, 22 (01)
  • [29] Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
    Eriko Miyawaki
    Hirotsugu Kenmotsu
    Yasushi Shintani
    Ikuo Sekine
    Takehito Shukuya
    Koichi Takayama
    Akira Inoue
    Isamu Okamoto
    Katsuyuki Kiura
    Kazuhisa Takahashi
    Nobuyuki Yamamoto
    Tomoya Kawaguchi
    Etsuo Miyaoka
    Ichiro Yoshino
    Hiroshi Date
    BMC Cancer, 22
  • [30] Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
    J Kupryjańczyk
    T Szymańska
    R Mądry
    A Timorek
    J Stelmachów
    G Karpińska
    A Rembiszewska
    I Ziółkowska
    E Kraszewska
    J Dębniak
    J Emerich
    M Ułańska
    A Płużańska
    M Jędryka
    M Goluda
    A Chudecka-Głaz
    I Rzepka-Górska
    M Klimek
    K Urbański
    J Bręborowicz
    J Zieliński
    J Markowska
    British Journal of Cancer, 2003, 88 : 848 - 854
12345